आयबॅकोतर्फे चॉकलेटचे स्वादिष्ट आणि क्रिमी डॉलॉप्स

-
आयबॅकोतर्फे चॉकलेटचे स्वादिष्ट आणि क्रिमी डॉलॉप्स

या सणांच्या हंगामाला केंद्रस्थानी ठेऊन आयबॅकोने त्यांच्या आईस्क्रीम आणि आईस्क्रीम केक्सच्या प्रमुख शृंखलेमध्ये चॉकलेट ओव्हरलोड आणि ब्लॅक फॉरेस्ट हे दोन नवीनव्हेरिएंट्स सादर केला आहेत. आनंददायक अशी ट्रीट असणारे आयबॅकोचे चॉकलेट ओव्हरलोड आईस्क्रीम केक हे सर्व चॉकलेट प्रेमींसाठी या उत्सवाच्या दिवसांसाठी एकपरिपूर्ण असे डेजर्ट आहे. चॉकलेट आईस्क्रीमचा थर असलेला या चॉकलेट केकवर चॉकलेट फ्लेक्स आणि बदामाचे बारीक तुकडे आहेत ज्यामुळे या चॉकलेट आईस्क्रीमकेकची लज्जत आणखीनच वाढली आहे. तसेच ग्राहकांसाठी चॉकलेट ओव्हरलोड आईस्क्रीमच्या स्वरूपातही उपलब्ध आहे.


पूर्णतः नवीन असा ब्लॅक फॉरेस्ट आईस्क्रीम केक हा अतिशय सुंदररित्या सजविलेला ब्लॅक फॉरेस्ट आणि व्हाईट चोको रास्पबेरी आईस्क्रीम यांचे मिश्रण असलेला केक असूनयावर चेरीज आणि चॉकलेट फ्लेक्स आहेत, तसेच यावर चॉकलेट स्टिक्सचे आवरण आहे. केकचा प्रत्येक तुकडा तुम्हाला स्वादिष्ट अशी दैवी अनुभूती देतो. आईस्क्रीम प्रेमींसाठीआयबकोमध्ये लोकप्रिय ब्लॅक फॉरेस्ट आईस्क्रीम सुद्धा उपलब्ध आहे.

Comments

Post a Comment

Popular posts from this blog

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

-
  Indegene acquires Trilogy Writing & Consulting GmbH,  a medical writing consultancy   India, March 27, 2024:  Indegene, a  digital-first, life sciences commercialization company , announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.   Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content. It applies its expertise and unique approaches to deliver quality medical writing output. Trilogy has a proven track record of more than 22 years of providing medical writing services to the biopharmaceutica
Read more

TiEcon Mumbai 2023, brilliantly showcased revolutionary ideas & impactful solutions to build an Anti-Fragile and Sustainable India

-
Image
TiEcon Mumbai 2023, brilliantly showcased revolutionary ideas & impactful solutions to build an Anti-Fragile and Sustainable India Mumbai, 09 June 2023 : The 16th Edition of TiEcon Mumbai, organised by TiE Mumbai at Jio Convention Centre, BKC culminated on an enthusiastic note with a call to build an Anti-Fragile and Sustainable India. It kick-started with marquee speakers focusing on ways to accelerate growth, drive more intelligent engagement, make conscious choices and methods to empower sustainable business building ideas. Speaking at the summit, Ranu Vohra, President- TiE Mumbai said, “It was great to see the energy of the startup eco system at work at TiECon 2023. There were lively debates on Mumbai’s roadmap to becoming the startup hub, Gen AI and its role in India and the opportunities, thus created. The session on funding availability held out promise that as the startups become “anti-fragile” and focus on unit economics and profitability we should see a renewed incre
Read more

REC DECLARES ITS FINANCIAL RESULTS FOR Q2 & H1 FY24

-
REC DECLARES ITS FINANCIAL RESULTS FOR Q2 & H1 FY24   REC RECORDS ITS HIGHEST EVER QUARTERLY PROFIT AT ₹3,773 CRORE Mumbai/New Delhi, November 01, 2023: REC limited, a ‘Maharatna’ company under the administrative control of the Ministry of Power, Government of India, and registered with RBI as Non-Banking Finance Company (NBFC), Public Financial Institution (PFI) and Infrastructure Financing Company (IFC), has today reported its unaudited financial results (Standalone) for the 2nd Quarter and Half Year ended 30th September 2023. Key highlights are as under:  Operational and Financial Highlights –Q2 FY24 vs Q2 FY23 (Standalone) • Sanctions: ₹ 1,04,366 crore vs. ₹ 84,889 crore, up 23%, Renewable sector constitutes for 24% • Disbursements: ₹ 41,598 crore vs. ₹ 17,827 crore, up 133% • Interest Income on Loan Assets: ₹ 11,213 crore vs. ₹ 9,534 crore, up 18% • Net Profit: ₹ 3,773 crore vs. ₹ 2,728 crore, up 38% • Total Comprehensive Income: ₹ 4,188 crore vs. ₹ 1,915 crore, up 1
Read more